Celesticaの空売り状況は、投資家がCelesticaの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Celestica (NYSE:CLS) 株価情報, 空売り情報

Celestica

Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity & Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity & Cloud Solutions segment.

Celestica Inc

Exchange Listed Funds Trust Cabana Target Leading Sector Aggressive ETF

Exchange Listed Funds Trust Cabana Target Leading Sector Conservative ETF

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical Inc

Trust for Professional Managers Convergence Long/Short Equity ETF

CLS HOLDINGS USA INC by CLS Holdings USA, Inc.

CLS Holdings USA Inc

Cleanspark Inc

Cabana Target Leading Sector Moderate ETF

CANADIAN LIFE COS SPLT by CANADIAN LIFE COS SPLIT CORP.

Canadian Life Companies Split Corp

Catalyst Bancorp Inc

CHINA OIL & GAS GROUP LTD by China Oil & Gas Group, Ltd.

China Oil And Gas Group Ltd

WIIM

Celestica shares are trading higher after Barclays initiated coverage on the stock with an Overweight rating and announced a price target of $91.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/64f99e440313770001b5ef69/george-wang">Barclays analyst George Wang</a> initiated coverage on Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with an Overweight rating and announced a price target of $91. Celestica shares closed at $72.32 on Monday. <a href="https://www.benzinga.com/quote/CLS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Tessa Romero initiated coverage on Upstream Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPB#NASDAQ">UPB</a>) with an Overweight rating and announced a price target of $38. Upstream Bio shares closed at $25.15 on Monday. <a href="https://www.benzinga.com/quote/UPB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5901e8ea0bd9910001e193f8/margaret-kaczor">William Blair analyst Margaret Kaczor</a> initiated coverage on CeriBell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBLL#NASDAQ">CBLL</a>) with an Outperform rating. CeriBell shares closed at $26.24 on Monday. <a href="https://www.benzinga.com/quote/CBLL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Julien Dumoulin-Smith initiated coverage on CMS Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMS#NYSE">CMS</a>) with a Buy rating and announced a price target of $76. CMS Energy shares closed at $68.39 on Monday. <a href="https://www.benzinga.com/quote/CMS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Chad Dillard initiated coverage on Eaton Corporation plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) with an Outperform rating and announced a price target of $382. Eaton shares closed at $331.13 on Monday. <a href="https://www.benzinga.com/quote/ETN/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ETN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="534" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05080021/image-28-1024x534.png" alt="" class="wp-image-630210" style="width:662px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05080021/image-28-1024x534.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05080021/image-28-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05080021/image-28-768x400.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05080021/image-28.png 1261w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41740698/top-3-health-care-stocks-youll-regret-missing-in-november">Top 3 Health Care Stocks You&#8217;ll Regret Missing In November</a></li>
</ul>

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CBLL

This Eaton Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Barclays analyst George Wang initiates coverage on Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Overweight rating and announces Price Target of $91.

Price Target

Barclays Initiates Coverage On Celestica with Overweight Rating, Announces Price Target of $91

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) stock upped 49.86% after the company announced it dosed its first patients in its Phase 1 clinical study of CAR-NK cell therapy for relapsed <a href="https://www.benzinga.com//node/41516867" target="_blank" rel="noreferrer noopener">B-Cell Non-Hodgkin Lymphoma</a>.</li>
<li>Stride, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>) shares rocketed 41.43% after the company reported better-than-expected first-quarter results and issued FY25 and second-quarter <a href="https://www.benzinga.com//node/41487340" target="_blank" rel="noreferrer noopener">revenue guidance above estimates</a>. Analysts boosted the <a href="https://www.benzinga.com/quote/lrn/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>PureCycle Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) <a href="https://www.benzinga.com//node/41409452" target="_blank" rel="noreferrer noopener">shares jumped 32.21%</a>.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) stock gained 31.68% last week. The stock has been volatile ahead of the upcoming U.S. election.</li>
<li>ZEEKR Intelligent Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>) gained 29.31%. Several U.S.-listed Chinese stocks gained after the People's Bank of China <a href="https://www.benzinga.com//node/41547149" target="_blank" rel="noreferrer noopener">injected 700 billion yuan</a> ($98.36 billion) into the banking system through its one-year medium-term lending facility, keeping the rate steady at 2.0%.</li>
<li>IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) stock gained 27.52%.</li>
<li>Herc Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRI#NYSE">HRI</a>) shares upped 21.76% after the company reported better-than-expected third-quarter revenue results and raised its FY24 equipment <a href="https://www.benzinga.com//node/41455862" target="_blank" rel="noreferrer noopener">rental revenue growth outlook</a>.</li>
<li>TeraWulf Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) stock gained 18.59% amid the rise in Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price. The company also proposed to raise $425 million via convertible senior debt notes.</li>
<li>iRhythm Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) stock escalated 20.76% after the company announced that it was granted FDA clearance for its 510(k) submission related to prior design changes <a href="https://www.benzinga.com//node/41462205" target="_blank" rel="noreferrer noopener">made to the Zio AT device</a>.</li>
<li>Celestica, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) shares rose 19.99% after the company reported better-than-expected third-quarter results and issued Q4 revenue guidance above estimates. Several analysts raised <a href="https://www.benzinga.com//node/41523564" target="_blank" rel="noreferrer noopener">the price target on the stock</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41560908/tesla-li-auto-and-microstrategy-are-among-top-10-large-cap-gainers-last-week-oct-21-oct-25-are-the" target="_blank" rel="noreferrer noopener">Tesla, Li Auto And MicroStrategy Are Among Top 10 Large Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41561358/genuine-parts-company-universal-health-services-and-topbuild-are-among-top-10-large-cap-losers-las" target="_blank" rel="noreferrer noopener">Genuine Parts Company, Universal Health Services, And TopBuild Are Among Top 10 Large Cap Losers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

Mid Cap

Movers

$BTC

IBRX

IONQ

IRTC

WULF

Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?

TD Cowen analyst Daniel Chan maintains Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Buy and raises the price target from $68 to $70.

TD Cowen Maintains Buy on Celestica, Raises Price Target to $70

Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Celestica and provided 12-month price targets. The average target is $68.6, accompanied by a high estimate of $75.00 and a low estimate of $58.00. Marking an increase of 12.09%, the current average surpasses the previous average price target of $61.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1729785650_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Celestica is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sheerin</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Paul Treiber</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Thanos Moschopoulos</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Daniel Chan</td>
<td>TD Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$68.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Matthew Sheerin</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$58.00</td>
<td>$58.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Celestica. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Celestica compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Celestica's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Celestica's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CLS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Celestica analyst ratings.</a>
<h2>Get to Know Celestica Better</h2>
Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity &amp; Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity &amp; Cloud Solutions segment.
<h3>Celestica's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Celestica's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 23.33%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Celestica's net margin is impressive, surpassing industry averages. With a net margin of 4.16%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Celestica's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.67%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Celestica's ROA stands out, surpassing industry averages. With an impressive ROA of 1.72%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.53, Celestica adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Celestica: Insights From 5 Analyst Reviews

Stifel analyst Matthew Sheerin maintains Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Buy and raises the price target from $58 to $70.

Stifel Maintains Buy on Celestica, Raises Price Target to $70

RBC Capital analyst Paul Treiber maintains Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Outperform and raises the price target from $65 to $75.

RBC Capital Maintains Outperform on Celestica, Raises Price Target to $75

U.S. stocks were mixed, with the Nasdaq Composite gaining around 100 points on Thursday.
Shares of United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) rose during Thursday's session after the company reported <a href="https://www.benzinga.com/news/earnings/24/10/41515619/delivery-giant-ups-breaks-revenue-miss-streak-after-10-quarters-stock-soars">better-than-expected quarterly EPS and sales.</a>
UPS reported consolidated revenue growth of 5.6% year-over-year to $22.2 billion, beating the consensus of $22.14 billion. Adjusted EPS was $1.76, up 12.1% YoY, above the consensus of $1.63.
United Parcel Service shares jumped 5% to $137.93 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) shares jumped 31.6% to $6.82 after the company said it has begun producing low volumes of its first B-sample cells and has begun shipping cells for automotive customer testing.</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) gained 22.8% to $337.89 after the company reported better-than-expected third-quarter financial results.</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) climbed 20.7% to $345.82 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance above estimates. Also, the company increased its fourth-quarter dividend.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) gained 18.7% to $71.65 after the company reported better-than-expected third-quarter EPS results.</li>
<li>LendingClub Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) gained 17.7% to $14.67 after the company reported better-than-expected third-quarter financial results.</li>
<li>American Coastal Insurance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) surged 16.8% to $12.09 after the company provided updates on hurricane loss amounts and announced it expects a positive net income for the third quarter.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 16.5% to $248.93 following better-than-expected quarterly earnings.</li>
<li>Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) climbed 15.6% to $66.48 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter revenue guidance above estimates.</li>
<li>Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) gained 15.2% to $33.33 after the company presented data from its ongoing Phase 1a/1b study of ZL-1310 for previously treated extensive-stage small cell lung cancer at the EORTC-NCI-AACR Symposium 2024.</li>
<li>Pegasystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) gained 14.2% to $79.66.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) surged 13.2% to $29.72 after the company announced it bagged a contract with the Space Development Agency as the prime contractor to the US Government.</li>
<li>ADT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>) gained 11.2% to $7.70 after the company reported better-than-expected third-quarter financial results and issued FY24 adjusted EPS above estimates.</li>
<li>Whirlpool Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) rose 10% to $109.18 following a third-quarter EPS beat and guidance above consensus estimates.</li>
<li>Plexus Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) rose 9.9% to $149.00 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 9.9% to $12.00 after Keybanc maintained an Overweight rating on the stock and raised its price target from $11 to $12.</li>
<li>CBRE Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NASDAQ">CBRE</a>) gained 9.7% to $135.12 after the company reported better-than-expected third-quarter financial results and raised its FY24 adjusted EPS guidance above estimates.</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) rose 8.2% to $629.72 following upbeat quarterly earnings.</li>
<li>Labcorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) gained 7.6% to $236.52 following strong quarterly earnings.</li>
<li>Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>) gained 7.5% to $377.11 following strong quarterly sales.</li>
<li>T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) gained 4.1% to $230.00 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41516316/jim-cramer-says-he-would-not-buy-this-health-care-stock-at-this-level-wait-for-a-pullbac">Jim Cramer Says He Would Not Buy This Health Care Stock At This Level: &#8216;Wait For A Pullback&#8217;</a></li>
</ul>

Intraday Update

ACIC

ASTS

CBRE

Laboratory Corporation Of America Holdings

PEGA

PLXS

POOL

RKLB

TMUS

TSLA

VKTX

ZLAB

UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday

BMO Capital analyst Thanos Moschopoulos maintains Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Outperform and raises the price target from $64 to $72.

BMO Capital Maintains Outperform on Celestica, Raises Price Target to $72

<h3>Gainers</h3>
<ul>
<li>CCSC Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) shares moved upwards by 75.3% to $3.05 during Thursday's pre-market session. The company's market cap stands at $35.3 million. </li>
<li>ZenaTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) shares increased by 40.9% to $2.48. The market value of their outstanding shares is at $43.8 million. </li>
<li>Sanmina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>) stock increased by 14.67% to $75.0. The market value of their outstanding shares is at $4.0 billion. </li>
<li>MaxLinear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) shares rose 11.16% to $16.53. The market value of their outstanding shares is at $1.3 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) shares rose 8.32% to $62.25. The company's market cap stands at $7.3 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) stock rose 6.06% to $77.28. The market value of their outstanding shares is at $100.1 billion. As per the news, the Q1 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Orangekloud Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) stock declined by 63.7% to $2.76 during Thursday's pre-market session. The company's market cap stands at $63.9 million. </li>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) stock declined by 29.95% to $0.1. The company's market cap stands at $2.0 million. </li>
<li>Zapata Computing Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZPTA#NASDAQ">ZPTA</a>) shares declined by 19.06% to $0.07. The company's market cap stands at $2.8 million. </li>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) shares fell 11.09% to $0.26. The market value of their outstanding shares is at $1.9 million. </li>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) stock decreased by 5.52% to $0.56. The market value of their outstanding shares is at $55.0 million. </li>
<li>Phunware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) stock declined by 5.24% to $13.4. The company's market cap stands at $151.9 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CCTG

LRCX

MLGO

ORKT

PHUN

SANM

SVRE

ZENA

ZPTA

12 Information Technology Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>CCSC Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) stock moved upwards by 77.0% to $3.08 during Thursday's pre-market session. The market value of their outstanding shares is at $35.6 million. </li>
<li>ZenaTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) shares moved upwards by 39.72% to $2.46. The market value of their outstanding shares is at $43.4 million. </li>
<li>Sanmina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>) shares rose 14.67% to $75.0. The company's market cap stands at $4.0 billion. </li>
<li>MaxLinear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) stock rose 11.16% to $16.53. The market value of their outstanding shares is at $1.3 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) stock moved upwards by 9.79% to $63.1. The company's market cap stands at $7.4 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Movano (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) stock rose 6.03% to $0.33. The market value of their outstanding shares is at $32.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Orangekloud Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) stock fell 63.1% to $2.81 during Thursday's pre-market session. The company's market cap stands at $65.0 million. </li>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) stock decreased by 29.95% to $0.1. The market value of their outstanding shares is at $2.0 million. </li>
<li>Zapata Computing Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZPTA#NASDAQ">ZPTA</a>) stock decreased by 20.05% to $0.07. The market value of their outstanding shares is at $2.8 million. </li>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) stock decreased by 10.74% to $0.26. The market value of their outstanding shares is at $1.9 million. </li>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) stock fell 5.52% to $0.56. The company's market cap stands at $55.0 million. </li>
<li>Phunware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) stock declined by 4.88% to $13.45. The company's market cap stands at $152.5 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MOVE

Celestica shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 revenue guidance above estimates.

<h3>Gainers</h3>
<ul>
<li>Rimini Street (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMNI#NASDAQ">RMNI</a>) stock rose 18.9% to $2.01 during Wednesday's after-market session. The market value of their outstanding shares is at $182.3 million. </li>
<li>Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) shares increased by 8.23% to $62.2. The market value of their outstanding shares is at $7.3 billion. As per the press release, Q3 earnings came out today. </li>
<li>MaxLinear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) stock rose 7.98% to $16.06. The company's market cap stands at $1.3 billion. As per the press release, Q3 earnings came out today. </li>
<li>Glimpse Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>) stock rose 6.63% to $0.77. The company's market cap stands at $13.9 million. </li>
<li>Blackboxstocks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBX#NASDAQ">BLBX</a>) stock increased by 6.16% to $3.1. The company's market cap stands at $10.9 million. </li>
<li>Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) shares moved upwards by 5.16% to $76.62. The company's market cap stands at $99.3 billion. The company's, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) stock fell 30.1% to $0.1 during Wednesday's after-market session. The company's market cap stands at $2.0 million. </li>
<li>TeraWulf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) stock declined by 8.13% to $5.88. The market value of their outstanding shares is at $2.2 billion. </li>
<li>SatixFy Communications (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SATX#AMEX">SATX</a>) stock decreased by 5.42% to $0.7. The company's market cap stands at $58.5 million. </li>
<li>Verb Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERB#NASDAQ">VERB</a>) stock declined by 4.64% to $10.45. The company's market cap stands at $7.6 million. </li>
<li>IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) stock decreased by 4.53% to $222.22. The company's market cap stands at $204.6 billion. The company's, Q3 earnings came out today. </li>
<li>Intrusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) shares declined by 4.27% to $0.71. The company's market cap stands at $4.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLBX

INTZ

RMNI

SatixFy Communications Ltd. Ordinary Share

SATX

VERB

VRAR

12 Information Technology Stocks Moving In Wednesday's After-Market Session

Earnings

Guidance

Celestica Sees Q4 2024 Revenue $9.60B Vs $9.45B Est.; Non-IFRS $3.85 Vs $3.62 Per Share Est.

Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) reported quarterly earnings of $1.04 per share which beat the analyst consensus estimate of $0.93 by 11.83 percent. The company reported quarterly sales of $2.50 billion which beat the analyst consensus estimate of $2.41 billion by 3.63 percent. This is a 22.37 percent increase over sales of $2.04 billion the same period last year.

Earnings Beats

Celestica Q3 2024 Adj EPS $1.04 Beats $0.93 Estimate, Sales $2.50B Beat $2.41B Estimate

Celestica's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) short percent of float has fallen 10.37% since its last report. The company recently reported that it has 3.14 million shares sold short, which is 2.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.31 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Celestica Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729620912_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Celestica has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Celestica's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Celestica's peer group average for short interest as a percentage of float is 3.17%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Celestica's Recent Short Interest

Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) is preparing to release its quarterly earnings on Wednesday, 2024-10-23. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Celestica to report an earnings per share (EPS) of $0.93.
The announcement from Celestica is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.10, leading to a 4.35% drop in the share price on the subsequent day.
Here's a look at Celestica's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.81</td>
<td>0.72</td>
<td>0.68</td>
<td>0.60</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.91</td>
<td>0.86</td>
<td>0.76</td>
<td>0.65</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-2.0%</td>
<td>2.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729609334_0.png" alt="eps graph" />
<h3>Performance of Celestica Shares</h3>
Shares of Celestica were trading at $56.68 as of October 21. Over the last 52-week period, shares are up 122.8%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Views on Celestica</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Celestica.
The consensus rating for Celestica is Buy, based on 6 analyst ratings. With an average one-year price target of $63.17, there's a potential 11.45% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Fabrinet, Plexus and IPG Photonics, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>The consensus among analysts is an Neutral trajectory for Fabrinet, with an average 1-year price target of $256.2, indicating a potential 352.01% upside.</li>
<li>The consensus among analysts is an Buy trajectory for Plexus, with an average 1-year price target of $147.25, indicating a potential 159.79% upside.</li>
<li>IPG Photonics received a Buy consensus from analysts, with an average 1-year price target of $100.0, implying a potential 76.43% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for Fabrinet, Plexus and IPG Photonics, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Celestica</td>
<td>Buy</td>
<td>23.33%</td>
<td>$256.10M</td>
<td>5.67%</td>
</tr>
<tr>
<td>Fabrinet</td>
<td>Neutral</td>
<td>14.85%</td>
<td>$92.45M</td>
<td>4.76%</td>
</tr>
<tr>
<td>Plexus</td>
<td>Buy</td>
<td>-5.96%</td>
<td>$94.42M</td>
<td>1.99%</td>
</tr>
<tr>
<td>IPG Photonics</td>
<td>Buy</td>
<td>-24.22%</td>
<td>$96.19M</td>
<td>0.88%</td>
</tr>
</tbody>
</table>

Key Takeaway:
In terms of revenue growth, Celestica is at the top among its peers. It also leads in gross profit margin. However, its return on equity is the lowest compared to others. Overall, Celestica is positioned favorably in revenue growth and gross profit, but lags behind in return on equity.
<h3>Delving into Celestica's Background</h3>
Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity &amp; Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity &amp; Cloud Solutions segment.
<h3>Celestica's Economic Impact: An Analysis</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Celestica's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 23.33% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Celestica's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.16% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Celestica's ROE excels beyond industry benchmarks, reaching 5.67%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Celestica's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.72%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.53.
<a href="https://www.benzinga.com/quote/CLS/earnings">To track all earnings releases for Celestica visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Celestica's Earnings Outlook

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock&#39;s price, do they really matter?
Let&#39;s take a look at what these Wall Street heavyweights have to say about Celestica (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cls#NYSE">CLS</a>) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
Celestica currently has an average brokerage recommendation&nbsp;of 1.57, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by seven brokerage firms. An ABR of 1.57 approximates between Strong Buy and Buy.
Of the seven recommendations that derive the current ABR, four are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 57.1% and 28.6% of all recommendations.
<h2>Brokerage Recommendation Trends for CLS</h2>
<img alt="Broker Rating Breakdown Chart for CLS" class="chart" src="https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/CLS_10112024.png" style="width:100%" title="" /> 
While the ABR calls for buying Celestica, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five &quot;Strong Buy&quot; recommendations for every &quot;Strong Sell&quot; recommendation.
In other words, their interests aren&#39;t always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock&#39;s price movement.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock&#39;s price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
<h2>Zacks Rank Should Not Be Confused With ABR</h2>
In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers&#39; vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company&#39;s changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
<h2>Is CLS a Good Investment?</h2>
In terms of earnings estimate revisions for Celestica, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $3.65.
Analysts&#39; steady views regarding the company&#39;s earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Celestica.
It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Celestica.
<a href="https://www.zacks.com/stock/news/2349269/wall-street-analysts-see-celestica-cls-as-a-buy-should-you-invest?cid=CS-BENZ-FT-fundamental_analysis|average_broker_rating-2349269">To read this article on Zacks.com click here.</a>

Tech

Wall Street Analysts See Celestica as a Buy: Should You Invest?

Celestica (CLS) is up 18.6%, or $10.66 to $68.13. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial n...

Celestica rises 18.6%

Celestica (TSE:CLS) has released an update. Celestica Inc. has received approval from the Toronto Stock Exchange for the early renewal of its norma...

Celestica Receives TSX Nod for Share Buyback Plan

Vertiv: A Strong Buy Amid Rising Cloud Infrastructure And Data Center Demand

Celestica Stock Is A Real AI Bargain Today

The Advance/Decline trend on the NYSE weakened; the Nasdaq A/D line  is outright scary.

Buckle Up And Use Volitility To Your Advantage

Buckle Up And Use Volatility To Your Advantage

Celestica: AI Capex Boom Still Promising, Baked-In Premium Triggers Downgrade

Barclays analyst George Wang CFA initiated coverage with a Buy rating on Celestica (CLS – Research Report) today and set a price target of $91.00. ...

Celestica (CLS) Receives a Buy from Barclays

Barclays analyst George Wang initiated coverage of Celestica (CLS) with an Overweight rating and $91 price target As a North American tier 1 electr...

Comments

Celestica

空売り

Celestica (NYSE:CLS) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル